"Buprenorphine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.
| Descriptor ID |
D002047
|
| MeSH Number(s) |
D03.132.577.249.150 D03.605.497.150 D03.633.400.686.150 D04.615.723.795.150
|
| Concept/Terms |
Subutex- Subutex
- Buprex
- Temgesic
- Temgésic
6029-M- 6029-M
- 6029 M
- 6029M
- RX-6029-M
- RX 6029 M
- RX6029M
|
Below are MeSH descriptors whose meaning is more general than "Buprenorphine".
Below are MeSH descriptors whose meaning is more specific than "Buprenorphine".
This graph shows the total number of publications written about "Buprenorphine" by people in this website by year, and whether "Buprenorphine" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 2 | 0 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 4 | 0 | 4 |
| 2002 | 2 | 0 | 2 |
| 2003 | 2 | 0 | 2 |
| 2004 | 3 | 1 | 4 |
| 2005 | 3 | 0 | 3 |
| 2006 | 4 | 1 | 5 |
| 2007 | 2 | 2 | 4 |
| 2008 | 2 | 0 | 2 |
| 2010 | 4 | 3 | 7 |
| 2011 | 9 | 1 | 10 |
| 2012 | 5 | 0 | 5 |
| 2013 | 11 | 1 | 12 |
| 2014 | 15 | 5 | 20 |
| 2015 | 10 | 2 | 12 |
| 2016 | 5 | 2 | 7 |
| 2017 | 7 | 3 | 10 |
| 2018 | 15 | 5 | 20 |
| 2019 | 13 | 7 | 20 |
| 2020 | 16 | 6 | 22 |
| 2021 | 30 | 2 | 32 |
| 2022 | 49 | 1 | 50 |
| 2023 | 34 | 0 | 34 |
| 2024 | 16 | 2 | 18 |
Below are the most recent publications written about "Buprenorphine" by people in Profiles.
-
Assessing the Safety, User Acceptability, Dissemination, and Reach of a Comprehensive Web-Based Resource on Medications for Opioid Use Disorder (MOUD Hub): Protocol for a Development and Usability Study. JMIR Res Protoc. 2024 Nov 07; 13:e57065.
-
Barriers and facilitators to implementing treatment for opioid use disorder in community hospitals. J Subst Use Addict Treat. 2024 Dec; 167:209520.
-
Association of Daily Doses of Buprenorphine With Urgent Health Care Utilization. JAMA Netw Open. 2024 Sep 03; 7(9):e2435478.
-
Average Daily Dose Trajectories for Episodes of Buprenorphine Treatment for Opioid Use Disorder. Subst Use Addctn J. 2024 Oct; 45(4):727-735.
-
Successful administration of extended-release buprenorphine in the emergency department. Am J Emerg Med. 2024 Oct; 84:189.e1-189.e3.
-
Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal. JAMA Netw Open. 2024 Jul 01; 7(7):e2420702.
-
Scaling Emergency Department Opioid Use Disorder Treatment Across California to Reduce Overdose Deaths, 2019-2023. Am J Public Health. 2024 09; 114(9):874-878.
-
Pharmacokinetics, pharmacodynamics and antinociceptive effects of buprenorphine following transdermal administration to horses. Vet Anaesth Analg. 2024 Sep-Oct; 51(5):520-530.
-
Observations on the effects of buprenorphine and methadone on illicit drug use. J Opioid Manag. 2024 May-Jun; 20(3):193-195.
-
Exemplar Hospital initiation trial to Enhance Treatment Engagement (EXHIT ENTRE): protocol for CTN-0098B a randomized implementation study to support hospitals in caring for patients with opioid use disorder. Addict Sci Clin Pract. 2024 04 11; 19(1):29.